Culture conversion and drug susceptibility in drug-resistant pulmonary tuberculosis with type 2 diabetes mellitus on oral regimens

doi:10.5493/wjem.122305

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

(1)

(0)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Exp Med. Sep 20, 2026; 16(3): 122305
Published online Sep 20, 2026. doi: 10.5493/wjem.122305

Table 4 Association of diabetic status with radiological, microbiological, and drug resistance features

Category	Variable	Diabetic (n = 61)	Pre-diabetic (n = 66)	Non-diabetic (n = 137)	P value
Radiological findings	Cavity	63.9	28.8	65.7	< 0.001
	Nodule	26.2	30.3	32.8	0.646
	Consolidation	42.6	36.4	39.4	< 0.001
	Bilateral involvement	50.8	47.0	50.4	0.024
	Upper zone involvement	63.9	68.2	62.0	0.695
	Middle zone involvement	55.7	45.5	49.6	0.508
	Lower zone involvement	70.5	48.5	53.3	0.028
Sputum smear grade	3+/2+ (high bacillary load)	80.3	60.6	72.2	0.087
Sputum smear grade	Scanty/negative	6.6/0.0	12.1/3.0	5.1/0.7
LPA resistance	rpoB	98.4	100.0	99.3	0.567
	inhA	31.1	13.6	12.4	0.004
	katG	95.1	84.9	94.2	0.043
Second-line LPA	LFX/MOXI/SLID (resistant)	0.0	0.0	0.0	0.000
DST (Z/MOXI/LZD)	Z resistance	83.6	74.2	68.6	0.086
DST (Z/MOXI/LZD)	MOXI/LZD resistance	0.0	0.0	0.0

DST: Drug susceptibility testing; Z: Pyrazinamide; LFX: Levofloxacin; LPA: Line probe assay; LZD: Linezolid; MOXI: Moxifloxacin; SLID: Sitafloxacin.

Full Size Table

Citation: Vats Y, Verma AK, Bajpai J, Kant S, Jain P, Bajaj D, Srivastava A, Kushwaha RAS, Kumar S, Garg R, Kumar A, Pradhan A. Culture conversion and drug susceptibility in drug-resistant pulmonary tuberculosis with type 2 diabetes mellitus on oral regimens. World J Exp Med 2026; 16(3): 122305
URL: https://www.wjgnet.com/2220-315x/full/v16/i3/122305.htm
DOI: https://dx.doi.org/10.5493/wjem.122305

Vats Y, Verma AK, Bajpai J, Kant S, Jain P, Bajaj D, Srivastava A, Kushwaha RAS, Kumar S, Garg R, Kumar A, Pradhan A. Culture conversion and drug susceptibility in drug-resistant pulmonary tuberculosis with type 2 diabetes mellitus on oral regimens. World J Exp Med 2026; 16(3): 122305 [DOI: 10.5493/wjem.122305]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.